EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of New KCNT1 ‐Epilepsy Drugs by In Silico , Cell, and Drosophila Modeling

Michael G Ricos iD, Bethan A Cole iD, Rashid Hussain iD, Grigori Y Rychkov iD, Zeeshan Shaukat iD, Nadia Pilati iD, Stephen P Muench iD, Katie J Simmons iD, Leanne M Dibbens iD, Jonathan D Lippiat iD

Annals of Neurology · 2025

DOI: 10.1002/ana.78031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2025. Verfasst von Michael G Ricos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Research Group, Clinical and Health Sciences, Australian Centre for Precision Health, University of South Australia, Adelaide, South Austral…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Potassium Channels, Nerve Tissue Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hyperactive KCNT1 potassium channels, caused by gain‐of‐function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug‐resistant seizures and, in cases with infantile onset, developmental regression can follow. KCNT1‐related disorders include epilepsy of infancy with migrating focal seizures and sleep‐related hypermotor epilepsy. There are currently no effective treatments for KCNT1 epilepsies, but suppressing overactive channels poses a potential strategy.

Methods

Using the KCNT1 channel structure we in silico screened a library of known drugs for those predicted to block the channel pore to inhibit channel activity. Cellular KCNT1 channel inhibition was analyzed using electrophysiology and Drosophila bang‐sensitive assays were used to analyze seizure suppression. Brain penetration of one drug was analyzed using liquid chromatography–mass spectrometry in a mouse.

Results

Eight known drugs were investigated in vitro for their effects on patient‐specific mutant KCNT1 channels, with 4 drugs showing significant reduction of K + current amplitudes. The action of the 4 drugs was then analyzed in vivo and 2 were found to reduce the seizure phenotype in humanized Drosophila KCNT1 epilepsy models. One drug, antrafenine, was shown to cross the blood–brain barrier in mice.

Interpretation

This study identified a known drug, antrafenine, that reduces KCNT1 channel activity, reduces seizure activity in Drosophila , and crosses the blood–brain barrier in the mouse, suggesting its potential applicability as a new treatment for KCNT1 epilepsy. The sequential in silico, in vitro, and in vivo mechanism‐based drug selection strategy used here may have broader application for other human disorders where a disease mechanism has been identified. ANN NEUROL 2025;98:1261–1274

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyPotassium ChannelsNerve Tissue ProteinsPotassium Channel BlockersAnimalsHumansDisease Models, AnimalMiceComputer SimulationDrosophilaHEK293 CellsAnimals, Genetically ModifiedMutationPotassium Channels, Sodium-Activated

Substanzen

AnticonvulsantsKCNT1 protein, humanPotassium ChannelsNerve Tissue ProteinsPotassium Channel BlockersPotassium Channels, Sodium-Activated

Autor:innen und Institutionen

  • Epilepsy Research Group, Clinical and Health Sciences, Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia.
  • School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
  • School of Biomedicine, University of Adelaide, Adelaide, South Australia, Australia.
  • South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • BioTiChe Drug Discovery Srl, Istituto di Ricerca Pediatrica Citta' della Speranza, Padova, Italy.
  • Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK.

ORCID-Profile: Michael G Ricos, Bethan A Cole, Rashid Hussain, Grigori Y Rychkov, Zeeshan Shaukat, Nadia Pilati, Stephen P Muench, Katie J Simmons, Leanne M Dibbens, Jonathan D Lippiat

Zitieren

APA

Ricos, M. G., Cole, B. A., Hussain, R., Rychkov, G. Y., Shaukat, Z., Pilati, N., Muench, S. P., Simmons, K. J., Dibbens, L. M., & Lippiat, J. D. (2025). Identification of New KCNT1 ‐Epilepsy Drugs by In Silico , Cell, and Drosophila Modeling. Annals of Neurology. https://doi.org/10.1002/ana.78031

Vancouver

Ricos MG, Cole BA, Hussain R, Rychkov GY, Shaukat Z, Pilati N, et al. Identification of New KCNT1 ‐Epilepsy Drugs by In Silico , Cell, and Drosophila Modeling. Annals of Neurology. 2025. doi:10.1002/ana.78031

BibTeX
@article{Ricos2025,
  author = {Ricos, Michael G and Cole, Bethan A and Hussain, Rashid and Rychkov, Grigori Y and Shaukat, Zeeshan and Pilati, Nadia and Muench, Stephen P and Simmons, Katie J and Dibbens, Leanne M and Lippiat, Jonathan D},
  title = {Identification of New KCNT1 ‐Epilepsy Drugs by In Silico , Cell, and Drosophila Modeling},
  journal = {Annals of Neurology},
  year = {2025},
  doi = {10.1002/ana.78031}
}
Kostenlos starten →